logo
Gender dysphoria should be treated with therapy instead of transition treatments, massive Donald Trump-ordered health report urges

Gender dysphoria should be treated with therapy instead of transition treatments, massive Donald Trump-ordered health report urges

Sky News AU02-05-2025
A sweeping review of transgender treatments on minors found 'deep uncertainty about the purported benefits' of many of those interventions — and urged doctors to put more of an emphasis on behavioral therapy when addressing gender dysphoria.
Researchers also concluded that many of the protocols for treating children with gender dysphoria became widely used before outcome studies determined whether or not they were safe practices, a massive 409-page Health and Human Services study revealed.
'The umbrella review found that the overall quality of evidence concerning the effects of any intervention on psychological outcomes, quality of life, regret, or long-term health, is very low,' HHS' Gender Dysphoria Report determined in its assessment of common studies on transgender treatments.
'This indicates that the beneficial effects reported in the literature are likely to differ substantially from the true effects of the interventions.'
President Trump signed an executive order in January ordering HHS to conduct a review of best practices for treating gender dysphoria within 90 days, which was released Thursday.
Transgender interventions in children that were scrutinized in the blockbuster HHS report include the use of puberty blockers, hormone therapy and surgeries.
While the report stressed it is not a 'clinical practice guideline,' the paper examined 17 systematic reviews of transgender treatments in minors and concluded that there was limited evidence to suggest those interventions had any 'meaningful improvement in mental health.'
In some instances, this was because studies did not properly measure track patient outcomes or studied individuals whose mental health was already at a 'high-functioning at baseline.'
'Multiple SRs [systematic reviews] have concluded that the evidence supporting the benefits of pediatric transition interventions—from PBs [puberty blockers] to CSH [cross-sex hormone therapy] and surgery—is of 'very low certainty,'' the HHS report said.
'All medical interventions carry the potential for harm.'
A lot of the research into transgenderism in question was conducted overseas. One of the most famous ones was the Dutch Protocol, which was originally published in 2006 and outlined 'highly medicalized' methods to treat young people with gender dysphoria, including puberty blockers.
For years, the Dutch Protocol was generally regarded as the gold standard guideline for treating young people struggling with gender dysphoria. The guidance has since been weakened over time, with some of its eligibility restrictions pared down.
Following the 2006 publication of the Dutch Protocol, there had been a sharp rise in transgender treatments in minors.
An estimated 3.3% of US adolescents consider themselves transgender, per the HHS report. Meanwhile, about 0.1% of 17-year-olds received hormonal treatment between 2018 and 2022.
But HHS researchers found that the Dutch Protocol was based on 'methodological flaws' that were 'largely overlooked' by the broader medical community since its publication.
'One of the study's limitations was its retrospective selection of 70 subjects from a larger 'intent-to-treat' group of 111 using non-randomized methods,' the HHS report said.
'This selection process inadvertently biased the sample toward cases with the most favorable prognoses, thereby limiting the generalizability of the study's findings.'
The HHS study cautioned that there is an 'extreme toxicity and polarization surrounding this field of medicine.'
Researchers in the HHS report frequently pointed to the United Kingdom's Cass Review, a sweeping four-year study by the National Health Service that similarly poked metholodical holes in more conventional research into transgenderism.
They also acknowledged that there's a 'growing international concern about pediatric medical transition' and that foreign countries are increasingly restricting transgender treatments on minors.
'There is currently no international consensus about best practices for the care of children and adolescents with gender dysphoria,' the HHS report stressed.
Still, the medical ethicists, doctors and methodologies that put the HHS review together highlighted the potential benefits of psychotherapeutic approaches to tackling gender dysphoria in minors.
HHS researchers admitted that 'direct evidence for psychotherapy' in children with gender dysphoria is limited, but argued there is 'available evidence to support the role of psychotherapy intreating children and adolescents with other mental health problems, like depression.
The HHS study has been met with mixed reactions from the medical community.
Susan Kressly, the president of the American Academy of Pediatrics, slammed the report, arguing that it relied too heavily upon a 'narrow set of data' and 'select perspectives.
'This report misrepresents the current medical consensus and fails to reflect the realities of pediatric care,' she said in a statement.
Dr. Stanley Goldfarb, chairman of Do No Harm, an organization that opposes so-called gender transition surgeries, hailed the HHS review for exposing 'a number of serious risks in the medical transition of young people.'
'The report cites a 'lack of robust evidence' for these medical procedures,' Goldfarb said in a statement. 'It is clearer now, more than ever, that we must end this misguided practice and replace it with evidence-based treatment for gender confused kids.'
Trump's directive for the HHS study was nestled in a broader January executive order to cut off government funding to support or promote operations for child sex changes.
National Institutes of Health (NIH) Director Dr. Jay Bhattacharya, whose agency helped conduct the HHS study, underscored the need to not let political agendas interfere with science.
'Our duty is to protect our nation's children—not expose them to unproven and irreversible medical interventions,' Bhattacharya said. 'We must follow the gold standard of science, not activist agendas.'
Now that it has been released, the HHS study, titled 'Treatment for Pediatric Gender Dysphoria: Review of Evidence and Best Practices,' is set to get peer-reviewed.
A modified version of the report is expected once the peer review process is complete.
Originally published as Gender dysphoria should be treated with therapy instead of transition treatments, massive Donald Trump-ordered health report urges
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

US stops visitor visas for people from Gaza
US stops visitor visas for people from Gaza

The Advertiser

time13 hours ago

  • The Advertiser

US stops visitor visas for people from Gaza

The US State Department says it is halting all visitor visas for individuals from Gaza while it conducts "a full and thorough" review. The department said a small number of temporary medical-humanitarian visas had been issued in recent days, but did not provide a figure. The US issued more than 3800 B1/B2 visitor visas, which permit foreigners to seek medical treatment in the United States, to holders of the Palestinian Authority travel document, according to an analysis of monthly figures provided on the department's website. That figure includes 640 visas issued in May. The Council on American-Islamic Relations condemned the move, saying it was the latest sign of the "intentional cruelty" of the Trump administration. The Palestine Children's Relief Fund said the decision to halt visas would deny access to medical care to wounded and sick children in Gaza. "This policy will have a devastating and irreversible impact on our ability to bring injured and critically ill children from Gaza to the United States for lifesaving medical treatment—a mission that has defined our work for more than 30 years," it said in a statement The State Department's move to stop visitor visas for people from Gaza comes after Laura Loomer, a far-right activist and an ally of President Donald Trump, said on social media on Friday that the Palestinian "refugees" had entered the US this month. Loomer's statement sparked outrage among some Republicans, with Randy Fine describing it as a "national security risk". Gaza has been devastated by a war that was triggered on October 7, 2023, when Palestinian militant group Hamas launched an attack on Israel, killing 1200 people and taking 251 hostages, according to Israeli figures. Israel's offensive against Hamas in Gaza since then has killed more than 61,000 Palestinians, according to local health officials. The US has not indicated that it would accept Palestinians displaced by the war. However, sources told Reuters that South Sudan and Israel are discussing a plan to resettle Palestinians. The US State Department says it is halting all visitor visas for individuals from Gaza while it conducts "a full and thorough" review. The department said a small number of temporary medical-humanitarian visas had been issued in recent days, but did not provide a figure. The US issued more than 3800 B1/B2 visitor visas, which permit foreigners to seek medical treatment in the United States, to holders of the Palestinian Authority travel document, according to an analysis of monthly figures provided on the department's website. That figure includes 640 visas issued in May. The Council on American-Islamic Relations condemned the move, saying it was the latest sign of the "intentional cruelty" of the Trump administration. The Palestine Children's Relief Fund said the decision to halt visas would deny access to medical care to wounded and sick children in Gaza. "This policy will have a devastating and irreversible impact on our ability to bring injured and critically ill children from Gaza to the United States for lifesaving medical treatment—a mission that has defined our work for more than 30 years," it said in a statement The State Department's move to stop visitor visas for people from Gaza comes after Laura Loomer, a far-right activist and an ally of President Donald Trump, said on social media on Friday that the Palestinian "refugees" had entered the US this month. Loomer's statement sparked outrage among some Republicans, with Randy Fine describing it as a "national security risk". Gaza has been devastated by a war that was triggered on October 7, 2023, when Palestinian militant group Hamas launched an attack on Israel, killing 1200 people and taking 251 hostages, according to Israeli figures. Israel's offensive against Hamas in Gaza since then has killed more than 61,000 Palestinians, according to local health officials. The US has not indicated that it would accept Palestinians displaced by the war. However, sources told Reuters that South Sudan and Israel are discussing a plan to resettle Palestinians. The US State Department says it is halting all visitor visas for individuals from Gaza while it conducts "a full and thorough" review. The department said a small number of temporary medical-humanitarian visas had been issued in recent days, but did not provide a figure. The US issued more than 3800 B1/B2 visitor visas, which permit foreigners to seek medical treatment in the United States, to holders of the Palestinian Authority travel document, according to an analysis of monthly figures provided on the department's website. That figure includes 640 visas issued in May. The Council on American-Islamic Relations condemned the move, saying it was the latest sign of the "intentional cruelty" of the Trump administration. The Palestine Children's Relief Fund said the decision to halt visas would deny access to medical care to wounded and sick children in Gaza. "This policy will have a devastating and irreversible impact on our ability to bring injured and critically ill children from Gaza to the United States for lifesaving medical treatment—a mission that has defined our work for more than 30 years," it said in a statement The State Department's move to stop visitor visas for people from Gaza comes after Laura Loomer, a far-right activist and an ally of President Donald Trump, said on social media on Friday that the Palestinian "refugees" had entered the US this month. Loomer's statement sparked outrage among some Republicans, with Randy Fine describing it as a "national security risk". Gaza has been devastated by a war that was triggered on October 7, 2023, when Palestinian militant group Hamas launched an attack on Israel, killing 1200 people and taking 251 hostages, according to Israeli figures. Israel's offensive against Hamas in Gaza since then has killed more than 61,000 Palestinians, according to local health officials. The US has not indicated that it would accept Palestinians displaced by the war. However, sources told Reuters that South Sudan and Israel are discussing a plan to resettle Palestinians. The US State Department says it is halting all visitor visas for individuals from Gaza while it conducts "a full and thorough" review. The department said a small number of temporary medical-humanitarian visas had been issued in recent days, but did not provide a figure. The US issued more than 3800 B1/B2 visitor visas, which permit foreigners to seek medical treatment in the United States, to holders of the Palestinian Authority travel document, according to an analysis of monthly figures provided on the department's website. That figure includes 640 visas issued in May. The Council on American-Islamic Relations condemned the move, saying it was the latest sign of the "intentional cruelty" of the Trump administration. The Palestine Children's Relief Fund said the decision to halt visas would deny access to medical care to wounded and sick children in Gaza. "This policy will have a devastating and irreversible impact on our ability to bring injured and critically ill children from Gaza to the United States for lifesaving medical treatment—a mission that has defined our work for more than 30 years," it said in a statement The State Department's move to stop visitor visas for people from Gaza comes after Laura Loomer, a far-right activist and an ally of President Donald Trump, said on social media on Friday that the Palestinian "refugees" had entered the US this month. Loomer's statement sparked outrage among some Republicans, with Randy Fine describing it as a "national security risk". Gaza has been devastated by a war that was triggered on October 7, 2023, when Palestinian militant group Hamas launched an attack on Israel, killing 1200 people and taking 251 hostages, according to Israeli figures. Israel's offensive against Hamas in Gaza since then has killed more than 61,000 Palestinians, according to local health officials. The US has not indicated that it would accept Palestinians displaced by the war. However, sources told Reuters that South Sudan and Israel are discussing a plan to resettle Palestinians.

Dow briefly hits record high on UnitedHealth's gains
Dow briefly hits record high on UnitedHealth's gains

Perth Now

time2 days ago

  • Perth Now

Dow briefly hits record high on UnitedHealth's gains

The blue-chip Dow has briefly hit a record high, as UnitedHealth's shares jumped after Berkshire Hathaway raised its stake in the health insurer, while investors assessed mixed data to gauge the Federal Reserve's monetary policy path this year. UnitedHealth Group gained 11.6 per cent to hit a more than two-month high after Warren Buffett's company revealed a new investment in the health insurer, while Michael Burry's Scion Asset Management also turned more bullish on the company. Rising costs in the broader healthcare sector and an about 40 per cent slump in heavyweight UnitedHealth's shares this year have left the Dow lagging its Wall Street peers on the road to record highs. The price-weighted index last scaled an all-time high on December 4. This week, however, the healthcare sector is the top performer on the S&P 500 and is on track for its best weekly performance since October 2022. Other insurance stocks Centene and Molina gained 5.2 per cent each. A report showed retail sales in July rose as expected, but the University of Michigan's index tracking consumer confidence fell more than expected to 58 as inflation expectations rose. "As long as consumer spending holds up and companies are able to retain workers because of that robust spending, the flywheel can continue to spin, pushing corporate profits and stock prices higher," said Chris Zaccarelli, chief investment officer for Northlight Asset Management, speaking on the retail sales figures. In early trading on Friday, the Dow Jones Industrial Average rose 99.11 points, or 0.22 per cent, to 45,011.45, the S&P 500 lost 7.39 points, or 0.11 per cent, to 6,461.15 and the Nasdaq Composite lost 30.70 points, or 0.14 per cent, to 21,681.10. Wall Street's main US stock indexes are on track for their second week of gains, buoyed by expectations that the Fed could restart its monetary policy easing cycle with a 25-basis-point interest rate cut in September. The central bank last lowered borrowing costs in December and said US tariffs could add to price pressures. However, recent labour market weakness and signs that tariff-induced inflation was yet to reflect in headline consumer prices have made investors confident of a potential dovish move next month. Still, Chicago Fed President Austan Goolsbee said recent data reports showed a stagflationary impulse from tariffs on the economy. On the trade front, US President Donald Trump said he would unveil tariffs on steel and semiconductors next week. Applied Materials tumbled 11.3 per cent after the chip equipment maker issued weak fourth-quarter forecasts. Intel rose 3.0 per cent after a report said the Trump administration was in talks for the US government to potentially take a stake in the chipmaker. Attention was also on a meeting between Trump and Russian counterpart Vladimir Putin that markets hope could pave the way for a resolution to the Ukraine conflict. Declining issues outnumbered advancers by a 1.22-to-1 ratio on the NYSE and a 1.31-to-1 ratio on the Nasdaq. The S&P 500 posted 8 new 52-week highs and no new lows, while the Nasdaq Composite recorded 52 new highs and 45 new lows.

FDA Waiting Room: For Aussie applicants, it's (mainly) business as usual
FDA Waiting Room: For Aussie applicants, it's (mainly) business as usual

News.com.au

time6 days ago

  • News.com.au

FDA Waiting Room: For Aussie applicants, it's (mainly) business as usual

Despite myriad pressures under the Trump regime, the FDA's drug and device approval process largely has been unfettered Telix Pharmaceuticals expects a company-making approval decision by the end of the month Painchek is among a string of device plays awaiting the agency's assent The US Food & Drug Administration's (FDA) resources have been cut more times than Martin Scorsese's then-edgy 1988 religious drama The Last Temptation of Christ. Word from within the powerful agency's imposing Maryland portals is that reviewers have struggled with their task of late because of lack of access to Zoom calls and similar everyday privations. For a legion of Australian drug and device makers awaiting company-making FDA approvals, it's a nervous time. But need they be worried? Business as usual In most cases, the risk of rejection is the same as being struck by lightning. The prevailing message is that despite mayhem at the agency in the Trump era, the approval process has not overly slowed unless the therapy is in a controversial realm (read: vaccines). Rather like the Kyiv denizens carrying out their lives amid a barrage of missiles, it's largely business as usual. A couple of notable rejections aside – namely Replimune Group's melanoma drug RP1, and see the Telix section below – so far this year the FDA has approved therapies for a range of cancers, autoimmune diseases, urinary tract infections and even menopausal hot flushes. PainChek (ASX:PCK) CEO Phil Daffas says the FDA does a 'superb' job under considerable pressure. The developer of a digital pain assessment, Painchek awaits FDA clearance under the de novo (new) device pathway (see below). 'Their M.O. (modus operandi) has been nothing but guidance and support,' he says. Aussie biotechs get the nod ASX life science have-a-go heroes have found favour, especially in the devices and diagnostics realm. In the drug space, the FDA last December greenlit Mesoblast's (ASX:MSB) graft-versus-host disease stem cell treatment, Ryoncil. In June, the agency approved CSL's (ASX:CSL) home-grown Andembry, the world's only prophylactic for hereditary angioedema. Device-wise, the agency approved Orthocell's (ASX:OCC) peripheral nerve repair tool Remplir. It also waved through EBR Systems' (ASX:EBR) groundbreaking left-ventricle assist device Wise and Nanosonics' (ASX:NAN) next-gen medical probe steriliser, Coris. 'Everyone was getting nervous towards the end, but we were very fortunate not to be impacted (by the FDA changes),' Nanosonics chief Michael Kavanagh says. 'The Australian medtech industry should be proud, not necessarily Nanosonics but Australia's ability to do these types of things.' Telix sweats on kidney imaging decision Is the FDA poised to make us further proud? Radiopharmacy giant Telix Pharmaceuticals (ASX:TLX) will know within three weeks whether the FDA has approved its kidney cancer imaging agent, Zircaix. The stakes could not be higher for the $6.8 billion market cap Telix, given Zircaix could well present a bigger market than for Illuccix, its approved prostate cancer imaging agent. So far at least, the FDA hasn't come back with any queries. Mind you, Telix hasn't had its way on other fronts. The FDA in late April knocked back the company's New Drug Application (NDA) for its brain cancer imaging agent, TLX101-CDx. As Telix CEO Dr Chris Behrenbruch pointedly noted, this was despite 'a robust consultation process prior to submission and during review of the NDA'. Painchek's painless process As with Telix, the FDA's decision will be company making for Painchek. Painchek's eponymous app is used across 110,000 nursing home beds in Australia, the UK and Canada – an addressable market of 500,000 beds. The US opens a market of three million beds, worth an estimated $100 million in annual recurring revenue. Painchek's FDA process started in 2019, when the company sought guidance on a supportive clinical trial (since successfully completed). 'The primary contact was the same person all the way through,' Daffas says. Painchek lodged its review in November 2024, after two pre-submission meetings with the agency. 'They recommended a two-step process, with feedback after each step,' he says. 'That was very helpful guidance. If there was room for a misunderstanding it got clarified in those two meetings.' Daffas says the FDA reps included experts in AI, privacy rules and cybersecurity and communications. 'Once again it's very helpful for us, as it makes for a more robust product.' Painchek expects an FDA decision around early October. 4D Medical breathes easy The developer of algo-based lung images tools, 4D Medical (ASX:4DX), has 'frequent flyer' status with the FDA which has approved eight of its devices already. These include its XV LVAS, which processes conventional X-ray scans 'to provide rich, functional lung health detail not available via other modalities'. 4D is now waiting to hear from the FDA about a ventilation perfusion imaging device. The company dubs the FDA's review as 'well progressed'. 4D has filed under the 510(k) predicate device route. According to the company, last year companies waited an average 112 days for an FDA yeah or nay. The current situation is 'aligning well with our experience in previous applications', the company says. Artrya is back for seconds … Artrya (ASX:AYA) says hard-to-detect coronary plaque is a key cause of heart attacks. This was an uncontroversial proposition for the FDA, which in late March approved Artrya's Salix Coronary Anatomy (SCA) platform. The AI-enabled tool provides point-of-care detection of high-risk plaque, a key predictor of heart attacks. Artrya has submitted for approval of a second device, Salix Coronary Plaque (SCP). SCP will extend the use to patients who have undergone a coronary CT angiogram. 'Once cleared, will enable us to deliver near real-time, AI-powered cardiac analysis to a large and growing market and unlock access to an established reimbursement code for plaque analysis,' co-founder (and now CEO) John Konstantopoulos says. The company expects to hear from the FDA by the end of September. … as is Echo IQ As with Artrya, heart diagnosis peer Echo IQ (ASX:EIQ) is no stranger to the FDA. In October last year the agency approved its EchoSolv AS, an AI-inspired device to detect aortic stenosis (narrowing of the heart valves). Echo IQ now is eyeing consent for a second product, EchoSolv HF, to detect heart problems early. It has teamed up with the esteemed Mayo Clinic to carry out a validation trial, the final requirement for FDA submission. Mayo also has exclusive rights to use EchoSolv HF across its 30 hospitals and possibly even co-brand the product. Echo IQ expects FDA approval by the end of the year. Imricor goes modular Still on matters of the heart, Imricor Medical Systems (ASX:IMR) is taking a Lego Masters approach to its maiden FDA application, for its cardiac ablation device, Vision-MR. By this we mean that Imricor has submitted its FDA in separate modules ('bricks'), to enable a rolling review. Vision-MR is the only ablation catheter designed for use with a magnetic resonance imaging (MRI) scanner, as opposed to x-ray fluoroscopy. The company last week said the second module was under review and it expects to submit the third module in the December quarter. 'We expect a steady string of 510(k) product submissions and approvals, which in turn helps accelerate the commercial launch across the US," the company says. In the March quarter European regulators re-approved Vision-MR, under tougher new rules. The European gatekeepers also approved Northstar, 'the world's only MRI-native 3D mapping and guidance system.' The FDA is also likely to approve Northstar in the current half. This will enable the company to start the initial rollout of its interventional cardiac magnetic resonance cardiac ablation labs. Patience, please Some applicants strike trouble with the FDA because they assume that reading the agency's intentions is easy as a Golden Book, when in fact they can be harder to fathom than Ulysses. As Telix's brain cancer setback attests, being on the same page is crucial. Amid the chaos of RFK Jr's early days as health czar, in March your columnist warned that while FDA approvals were often company making, don't expect quick returns. That's because shares may have run hard in anticipation of the happy event and profit takers move in. Often, companies raise capital on positive news and this constrains the share price. EBR did the rounds for $66 million in May and Mesoblast in January raised a monstrous $260 million. FDA approval is only the first step to commercialisation: securing reimbursement and distribution network are just as important. But without consent, companies aren't even in the starting block to tackle the world's richest – albeit more quixotic – healthcare market. If anyone needs reminding, the US accounts for roughly half of the world's healthcare expenditure.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store